Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23


Maud Kamal

Medical Oncology Department
Institut Curie


Maud Kamal manages and coordinates precision medicine and European projects at Institut Curie where she is also in charge of the scientific management of the Molecular Tumour Board. She is currently involved in several projects among which RAIDs (Rational Molecular Assessment Innovative Drug selection), the first biobanking study for cervical cancer patients in Europe aiming towards implementing innovative treatment strategies based on patient molecular stratification. She has also been in charge of the management of the SHIVA trial, the first randomised precision medicine clinical trial.

Following a BSc and a Teaching Diploma in Sciences from the American University of Beirut, Lebanon, in 1999, she received a scholarship for a PhD programme in molecular and cell biology from the University of Sherbrooke, Canada. After receiving her MSc in Cell Biology, she pursued her PhD studies in Molecular and Cellular Biology at the University of Paris XII.  In 2007, she joined Institut Cochin in France for a Postdoctoral position and worked in collaboration with the research institute of SERVIER. She also holds a University Diploma in « Economic Valorisation of Research » from University of Paris VI.

Maud Kamal has published over 40 peer-reviewed papers in international journals.

Last update: July 2017

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.